PDX model details
| PDX ID |
382M |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Renal |
Current Generation (* indicates number of generations grown in Castrate host) |
11 |
| Average PDX Generation Time (days +/- SEM) |
41 ± 4 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
382M |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 382M |
CHD1 |
-14.8535 |
0.0000676 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
AR |
-5.06364 |
0.0299015 |
GSR |
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
FANCA |
-1.42678 |
0.74392 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
TP53 |
-1.40254 |
0.756525 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
PTEN |
-0.96689 |
1.02322 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
SUFU |
-0.96689 |
1.02322 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
KMT2C |
-0.949299 |
1.03577 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
RB1 |
-0.923221 |
1.05466 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
CDKN1B |
-0.861204 |
1.10099 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
KMT2C |
0.537576 |
2.90306 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
PIK3CA |
0.595957 |
3.02295 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
CTNNB1 |
0.643841 |
3.12497 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
PIK3CB |
0.971282 |
3.92116 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 382M |
MYC |
1.16424 |
4.4823 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
Clinical Information
| Sample Number |
382M |
| Sample Site |
Liver |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, cabazitaxel, abiraterone |
| |
|
Patient Information
| Patient Number |
175/382 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 382M |
BTK |
181 |
0.99 |
missense_variant |
'12/19 |
. |
26.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
PTEN |
227 |
0.98 |
missense_variant |
'5/9 |
. |
27.2 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
PTCH1 |
393 |
0.51 |
missense_variant |
'9/24 |
0.0007269 |
23.6 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
SETD2 |
404 |
0.48 |
missense_variant |
'3/21 |
0.0005031 |
29.4 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
LRP2 |
351 |
0.47 |
missense_variant |
'22/79 |
. |
0.437 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
SPOP |
370 |
0.46 |
missense_variant |
'7/12 |
4.07E-06 |
23.7 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
GRIN2A |
1018 |
0.35 |
missense_variant |
'13/14 |
. |
24.9 |
Uncertain_significance
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
EPHA5 |
359 |
0.32 |
frameshift_variant |
'1/18 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
MYCN |
234 |
0.31 |
inframe_deletion |
'2/3 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 382M |
AR |
381 |
0.27 |
GSR |
'1/8 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
No information in Drug dosing Table